Necitumumab
Necitumumab Uses, Dosage, Side Effects, Food Interaction and all others data.
Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist. It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation, thereby preventing further activation of EGFR which is beneficial in NSCLC as many patients have increased protein expression of EGFR. Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC).
Trade Name | Necitumumab |
Availability | Prescription only |
Generic | Necitumumab |
Necitumumab Other Names | Necitumumab |
Related Drugs | Opdivo, methotrexate, Keytruda, pembrolizumab, cisplatin, Tagrisso, Avastin |
Weight | 16mg/ml, |
Type | Intravenous Solution, Intravenous |
Groups | Approved, Investigational |
Therapeutic Class | |
Manufacturer | |
Available Country | United States |
Last Updated: | September 19, 2023 at 7:00 am |
Uses
Necitumumab is a monoclonal antibody used to treat metastatic squamous non-small cell lung cancer.
Necitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.
Necitumumab is also used to associated treatment for these conditions: Metastatic Non-Small Cell Lung Cancer
How Necitumumab works
Necitumumab is an EGFR antagonist that functions by binding to epidermal growth factor receptor (EGFR) and preventing binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression. Binding of necitumumab to EGFR induces receptor internalization and degradation.
Toxicity
The poor safety profile of necitumumab has been one of the major limitations of its use. Rigorous monitoring of the following adverse events is recommended for the use of this drug: cardiopulmonary arrest, hypomagnesia, venous and arterial thromboembolic events, dermatologic toxicities, and infusion-related reactions. Due to observations of increased toxicity and mortality in treatment of non-squamous NSCLC, necitumumab is only recommended for the treatment of squamous NSCLC in combination with cisplatin and gemcitabine. Animal studies suggest potential embryo-fetal toxicity.
Food Interaction
No interactions found.Necitumumab Disease Interaction
Major: CV/electrolyte imbalance, dermatologic toxicities, ocular disorders, thromboembolic disordersModerate: renal/liver impairment
Volume of Distribution
Steady state volume of distribution is 7.0 L.
Half Life
Elimination half life is approximately 14 days.
Clearance
14.1 mL/h
Innovators Monograph
You find simplified version here Necitumumab